Spotlight On: Alluzience

24 Mar 2023

A look at the next step in botulinum toxin formulation

Botulinum toxin is the bread and butter of aesthetics, and year on year continues to be the most popular treatment in medical aesthetic clinics.1 All approved BoNT-A products (or formulations) in Europe come in powder form and require reconstitution with sodium chloride before use – until now. With continuing advancements in technology, this month sees the official launch of Alluzience at ACE 2023 – the first ever ready-to-use neuromodulator (ABont-A liquid toxin).

What is Alluzience?

Produced by global pharmaceutical company Galderma, Alluzience is a liquid formulation that avoids any calculations to reconstitute the product from powder to liquid form.2 It is approved for treatment of moderate to severe glabellar lines.2

Aesthetic practitioner Dr Kuldeep Minocha, who was one of the first UK practitioners to use the toxin in the UK, comments, “Alluzience is a brand new abobotulinumtoxin that comes reconstituted straight from the manufacturer, which makes my life a lot easier! I’m one of the earliest users of Alluzience in the UK and have been using it since March 2022. I’ve injected around 300 patients so far and I can tell you that every single patient has been completely blown away with the result and has requested repeat treatment with this particular product.”

Clinical studies

According to the company, the decision to make ABont-A liquid toxin available to the UK after previously being launched in 2021 was based on pooled data from two pivotal trials run by Galderma. The two studies looked at a total of 372 patients with moderate to severe glabellar lines who were treated with either ABont-A liquid toxin (n=250) or placebo (n=122). This data demonstrated that more than 50% of patients reported an effect within two to three days, including 23% of patients within one day.2 The results were demonstrated to last for up to six months after injection with ABont-A liquid toxin.2 The responder rate at day 29 was significantly higher for patients treated with ABont-A liquid toxin compared to the placebo (p<0.0001).2

Another 2020 study of 185 patients looked to evaluate the six-month efficacy, safety and patient satisfaction of this brand new, ready-to-use abobotulinumtoxinA solution for injection (ASI) of glabellar lines. Results showed that the ASI was significantly efficacious for improving moderate or severe glabellar lines vs. placebo by investigator and patient assessment. The ASI was associated with high patient satisfaction, and comparable safety profile to abobotulinumtoxinA.3

Other study outcomes on patient satisfaction one-month following injection indicate that 85.2% of the patients receiving ABont-A liquid toxin were either satisfied or very satisfied compared to 9% for placebo patients.2 Alongside this, at one month, more than eight out of 10 (85%) patients treated with ABont-A liquid toxin reported improvements in their psychological wellbeing; feeling more attractive, confident, self-accepting and happy.2

Recently, a 2022 study on 150 female subjects between 18 and <65 years of age with moderate to severe glabellar lines showed that 94% felt that the treatment session was good and exceeded their expectations, whilst 77% reported improvement in the appearance of their glabellar lines at month six.4 Furthermore, 100% of the investigators strongly agreed or agreed that Alluzience saves time, is easy to use, easy to learn and met their expectations. In addition, 81% preferred using Alluzience over another well-used toxin.4

The majority of adverse reactions reported with ABont-A liquid toxin in clinical trials were of mild to moderate pain and this was reversible.2 The most frequently reported adverse reactions were headaches and injection site pain.2

Treatment considerations

Galderma explains that Alluzience should only be administered by doctors, nurses and dentists, with appropriate qualifications and expertise in this treatment using the required equipment.2 Dosing and treatment intervals depend on assessment of the individual patient’s response/reaction to the procedure, and the treatment interval should be no more frequent than every three months.

Upgrade to become a Full Member to read all of this article.